Apela was recently identified as a new ligand of the apelin peptide jejunum (APJ) receptor. The purpose of this study was to investigate the role of apela in post‐myocardial infarction (post‐MI) recovery from cardiorenal damage. A murine MI model was established, and apela was then infused subcutaneously for two weeks. Echocardiographs were performed before and after infarction at the indicated times. Renal function was evaluated by serum and urine biochemistry. Immunohistochemistry of heart and kidney tissue was performed by in situ terminal deoxynucleotidyl transferase‐mediated dUPT nick end‐labelling reaction. Compared to the control group (MI/vehicle), the average value of the left ventricular ejection fraction in apela‐treated mice increased by 32% and 39% at 2‐ and 4‐week post‐MI, respectively. The mean levels of serum blood urea nitrogen，creatinine, N‐terminal pro‐brain natriuretic peptide and 24‐hour urine protein were significantly decreased at 4‐week post‐MI in apela‐treated mice relative to that of control animals. At the cellular level, we found that apela treatment significantly reduced myocardial fibrosis and cellular apoptosis in heart and kidney tissue. These data suggest that apela improves cardiac and renal function in mice with acute MI. The peptide may be potential therapeutic agent for heart failure.

中文翻译：

---

Apela可改善急性心肌梗塞小鼠的心脏和肾脏功能。

Apela最近被确定为apelin肽空肠（APJ）受体的新配体。这项研究的目的是探讨apela在心肌梗死后心肌梗死（心梗后）恢复中的作用。建立了鼠类MI模型，然后将apela皮下注入两周。在指定的时间在梗死前后进行超声心动图检查。通过血清和尿液生化评估肾功能。心脏和肾脏组织的免疫组织化学通过原位末端脱氧核苷酸转移酶介导的dUPT缺口末端标记反应进行。与对照组（MI /车辆）相比，经MILE治疗的小鼠在MI后2周和4周时左心室射血分数的平均值分别增加了32％和39％。与对照组相比，经Apela处理的小鼠在MI后4周时的平均血尿素氮，肌酐，N端脑钠肽和24小时尿蛋白的平均水平显着降低。在细胞水平上，我们发现apela治疗显着减少了心脏和肾脏组织中的心肌纤维化和细胞凋亡。这些数据表明，apela可改善急性心肌梗死小鼠的心脏和肾脏功能。该肽可能是心力衰竭的潜在治疗剂。这些数据表明，apela可改善急性心肌梗死小鼠的心脏和肾脏功能。该肽可能是心力衰竭的潜在治疗剂。这些数据表明，apela可改善急性心肌梗死小鼠的心脏和肾脏功能。该肽可能是心力衰竭的潜在治疗剂。